Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.43 |
| ▸ | TUBB | P07437 | 4/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183455 | 0.85 | ACHE (0.50) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL30927177 | 0.84 | TPMT (0.53) | ACHECYP3A4MAPTCA9TUBB4A | |
| SCHEMBL29215248 | 0.84 | TPMT (0.53) | ACHECYP3A4MAPTCA9TUBB4A | |
| SCHEMBL27743867 | 0.80 | MAPT (0.38) | ACHECYP3A4MAPTCA9HTR2A | |
| SCHEMBL5208819 | 0.79 | HTR2A (0.56) | ACHEMAPTPTGS2HTR2AHTR2C | |
| SCHEMBL5240307 | 0.79 | ACHE (0.38) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL4114610 | 0.79 | GAA (0.42) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL31538448 | 0.79 | ERN1 (0.49) | ACHECYP3A4MAPTCYP1A2KDM4E | |
| SCHEMBL28295701 | 0.79 | ERN1 (0.49) | ACHECYP3A4MAPTCYP1A2KDM4E | |
| SCHEMBL19351317 | 0.79 | ACHE (0.59) | ACHECYP3A4MAPTCA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-11-07 | — | — | US | disclosed |
| US-20240352307-A1 | ACCESSING AND MODULATING THE COLOR AND VIBRANCY OF ANODICALLY COLORING ELECTROCHROMIC MOLECULES | GEORGIA TECH RESEARCH CORPORATION | 2024-10-24 | — | — | US | disclosed |
| EP-4413004-A1 | MACROCYCLIC COMPOUNDS HAVING ENT1 INHIBITING ACTIVITY | iTeos Belgium SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| CN-118076610-A | Macrocyclic compounds with ENT1 inhibitory activity | ITEOS比利时公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023142486-A1 | BORON-NITROGEN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 季华恒烨(佛山)电子材料有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023142485-A1 | BORON-NITROGEN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 季华恒烨(佛山)电子材料有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023059739-A1 | MACROCYCLIC COMPOUNDS HAVING ENT1 INHIBITING ACTIVITY | iTeos Belgium SA (US) | 2023-04-13 | — | — | WO | disclosed |
| US-11478445-B2 | Method for treating acute myeloid leukemia | BIONOMICS LTD. (AU) | 2022-10-25 | — | — | US | disclosed |
| US-6498169-B1 | CELL ADHESION AND INFILTRATION INHIBITORS; ANTIASTHMATICS, ANTIALLERGENS, ANTIRHEUMATICS, ANTIARTERIOSCLEROTICS, ANTIINFLAMMATORIES AND ANTI SJOGREN'S SYNDROME AGENTS | KOWA CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| WO-2002060872-A1 | SYNTHESIS FOR THE PREPARATION OF COMPOUNDS FOR SCREENING AS POTENTIAL TUBULIN BINDING AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2002-08-08 | — | — | WO | disclosed |
| US-6395753-B1 | ANTIHISTAMINES, ANTIALLERGENS, ANTIARTHRITIC AGENTS | KOWA CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1103554-A1 | Derivatives of dihydrofuro-(3,4-b)-quinolein-1-ones, process of préparation and phamaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-05-30 | — | — | EP | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| EP-0790993-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015125-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5482960-A | Nonpeptide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | ACHE 3555/4885CYP3A4 4225/4885MAPT 2614/4885 |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | ACHE 3624/4885CYP3A4 3606/4885MAPT 4654/4885 |
| US-20240352307-A1 | ACCESSING AND MODULATING THE COLOR AND VIBRANCY OF ANODICALLY COLORING ELECTROCHROMIC MOLECULES | VDAC2, VDAC3, RARG | ACHE 421/4885CYP3A4 468/4885MAPT 2439/4885 |
| US-11478445-B2 | Method for treating acute myeloid leukemia | MCL1, NPM1, MYADM | ACHE 4659/4885CYP3A4 1036/4885MAPT 4830/4885 |
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | ACHE 802/4885CYP3A4 609/4885MAPT 3453/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ACHE 3555/4885CYP3A4 4225/4885MAPT 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.